Male, n (%) |
30 |
19 (63%) |
Age at baseline visit (years old), median (IQR) |
30 |
64
(17) |
Duration of follow-up (months), median (IQR) |
30 |
21
(37) |
Past medical history |
|
|
Personal history of allergy or atopic conditions, n (%) |
30 |
6 (20%) |
- Urticaria, n (%) |
|
0 (0%) |
- Atopic dermatitis, n (%) |
|
1 (3%) |
- Asthma, n (%) |
|
2 (7%) |
- EENT atopy, n (%) |
|
1 (3%) |
- Food allergy, n (%) |
|
2 (7%) |
- Drug allergy, n (%) |
|
0 (0%) |
Personal history of autoimmune diseases, n (%) |
30 |
0
(0%) |
Familial history of AE, n (%) |
30 |
4 (13%) |
Familial history of allergy or atopic conditions, n (%) |
30 |
5 (17%) |
- Urticaria, n (%) |
|
0 (0%) |
- Atopic dermatitis, n (%) |
|
0 (0%) |
- Asthma, n (%) |
|
3 (10%) |
- EENT atopy, n (%) |
|
2 (7%) |
- Food allergy, n (%) |
|
0 (0%) |
- Drug allergy, n (%) |
|
0 (0%) |
Incriminated treatment |
|
|
Therapeutic class(es) |
30 |
|
- ACEi alone, n (%) |
|
25 (83%) |
- ACEi + ARBs, n (%) |
|
1 (3%) |
- ACEi + DPP-4i, n (%) |
|
4 (13%) |
Duration of exposure (total in case of multiple exposures)
(months), median (IQR) |
26 |
23 (103) |
Characteristics of AE attack - onset |
|
|
Number of attacks, median (IQR) |
29 |
2 (2) |
Time span between first and last attacks (or first attack and
consultation) (months), median (IQR) |
30 |
2 (20) |
Time of day of attack onset |
24 |
|
- Attacks preferentially occur in the evening or at night (or are
noticed when waking up), n (%) |
|
6 (25%) |
- Attacks preferentially occur in the morning or the afternoon, n (%) |
|
8 (33%) |
- No preferential time of day identified, n (%) |
|
10
(42%) |
Presence of prodromes, n (%) |
29 |
1 (3%) |
Triggering factor, n (%) |
30 |
3 (10%) |
Characteristics of AE attack - plateau |
|
|
Affected sites |
30 |
|
- Lips, n (%) |
|
15 (50%) |
- Tongue, n (%) |
|
14 (47%) |
- Uvula, n (%) |
|
3 (10%) |
- Oral cavity (excluding lips, tongue and uvula), n (%) |
|
7
(23%) |
- Throat (pharynx, larynx), n (%) |
|
9 (30%) |
- Face (excluding lips), n (%) |
|
3 (10%) |
- Digestive tract, n (%) |
|
0 (0%) |
- Genitalia, n (%) |
|
0 (0%) |
- Upper limbs, n (%) |
|
0 (0%) |
- Lower limbs, n (%) |
|
0 (0%) |
Cutaneous symptoms, n (%) |
30 |
1 (3%) |
- Urticaria, n (%) |
|
0 (0%) |
- Pruritus, n (%) |
|
1 (3%) |
ENT symptoms, n (%) |
30 |
10 (33%) |
- Dyspnea, n (%) |
|
4 (13%) |
- Dysphonia, n (%) |
|
7 (23%) |
- Dysphagia, n (%) |
|
5 (17%) |
Digestive symptoms, n (%) |
30 |
0 (0%) |
Characteristics of AE attack - resolution |
|
|
Occurrence of attacks resolving without treatment, n (%) |
30 |
9 (30%) |
Occurrence of attacks resolving <24h without treatment, n (%) |
30 |
8 (27%) |
Duration of attacks without treatment (hours), median (IQR) |
9 |
24
(42) |
Treatments of attacks |
|
|
Antihistamines, n (%) |
30 |
19 (63%) |
- effective treatment, n (%) |
19 |
1 (5%) |
Corticosteroids, n (%) |
30 |
18 (60%) |
- effective treatment, n (%) |
18 |
1 (6%) |
Adrenalin, n (%) |
30 |
3 (10%) |
- effective treatment, n (%) |
3 |
0 (0%) |
Tranexamic acid, n (%) |
30 |
10 (30%) |
- effective treatment, n (%) |
10 |
7 (70%) |
Bradykinin B2-receptor antagonist (icatibant), n (%) |
30 |
19
(63%) |
- effective treatment, n (%) |
19 |
15 (79%) |
Human or recombinant C1-INH concentrate, n (%) |
30 |
4
(13%) |
- effective treatment, n (%) |
4 |
3 (75%) |
Upper airway control procedures, n (%) |
30 |
0 (0%) |
Biological characteristics |
|
|
Low CH50 levels, n (%) |
30 |
0 (0%) |
Low C4 levels, n (%) |
30 |
0 (0%) |
Low C1-INH levels, n (%) |
30 |
0 (0%) |
Low C1-INH activity, n (%) |
30 |
0 (0%) |
High IgE levels, n (%) |
8 |
4 (50%) |
High tryptase levels, n (%) |
13 |
1 (7%) |
Hyper-eosinophilia, n (%) |
27 |
2 (7%) |
Abnormal TSH, n (%) |
20 |
0 (0%) |
Positive anti-thyroperoxydase and/or anti-thyroglobulin antibodies, n
(%) |
15 |
0 (0%) |